At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 530 enrolled
Drug / intervention
RSVPreF3 OA investigational vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With Herpes Zoster Recombinant Subunit (HZ/su) Vaccine in Adults Aged 50 Years and Older
In Brief
A Phase 3 clinical trial evaluating RSVPreF3 OA investigational vaccine and HZ/su vaccine for Respiratory Syncytial Viruses and Respiratory Syncytial Virus Infections. Completed, enrolled 530 participants across 31 sites in 2 countries.
Detailed Summary
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged \>=50 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedJul 2023
Enrollment StartJul 2023
Primary CompletionFeb 2024
Study CompletionJul 2024
TodayJul 2026
First PostedJul 28, 2023
Enrollment StartJul 28, 2023
Primary CompletionFeb 19, 2024
Study CompletionJul 29, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.9 years ago
Interventions
RSVPreF3 OA investigational vaccinebiological
One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
HZ/su vaccinebiological
Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.